Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months With ATA188 In Patients With Progressive Multiple Sclerosis In Late-Breaking e-Poster At 2020 European Academy Of Neurology Virtual Congress
Benzinga Newsdesk